(NASDAQ: VRCA) Verrica Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.52%.
Verrica Pharmaceuticals's earnings in 2025 is -$26,014,000.On average, 8 Wall Street analysts forecast VRCA's earnings for 2025 to be -$12,970,980, with the lowest VRCA earnings forecast at -$19,623,494, and the highest VRCA earnings forecast at -$5,679,786. On average, 8 Wall Street analysts forecast VRCA's earnings for 2026 to be -$11,444,982, with the lowest VRCA earnings forecast at -$14,229,358, and the highest VRCA earnings forecast at -$9,864,891.
In 2027, VRCA is forecast to generate -$1,839,169 in earnings, with the lowest earnings forecast at -$1,767,045 and the highest earnings forecast at -$1,893,262.